ANNEXON, INC. Payments to Acquire Debt Securities, Available-for-sale
ANNEXON, INC. (ANNX) reported Payments to Acquire Debt Securities, Available-for-sale of $15.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-12
- ANNEXON, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $9.90M, a 83.14% decline year-over-year.
- ANNEXON, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $5.94M, a 90.38% decline year-over-year.
- ANNEXON, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $65.02M, a 62.20% decline year-over-year.
- ANNEXON, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $26.68M, a 81.69% decline year-over-year.
- ANNEXON, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $212.21M, a 63.66% decline from fiscal 2024.
- ANNEXON, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $583.93M, a 440.24% increase from fiscal 2023.
- ANNEXON, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $108.09M, a 4.51% decline from fiscal 2022.
- ANNEXON, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $113.20M, a 49.82% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $15.84M 10-Q · filed 2026-08-12 | $80.86M derived: sum of 3 quarters · filed 2026-08-12 | $107.54M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $5.94M 10-Q · filed 2026-05-07 | $70.97M derived: sum of 2 quarters · filed 2026-05-07 | $97.65M derived: sum of 3 quarters · filed 2026-05-07 | $156.35M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $65.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $91.70M derived: sum of 2 quarters · filed 2026-03-30 | $150.41M derived: sum of 3 quarters · filed 2026-08-12 | $212.21M 10-K · filed 2026-03-30 |
| 2025-09-30 | $26.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $85.38M derived: sum of 2 quarters · filed 2026-08-12 | $147.19M 10-Q · filed 2025-11-10 | $319.22M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $58.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $120.51M 10-Q · filed 2026-08-12 | $292.54M derived: sum of 3 quarters · filed 2026-08-12 | $438.26M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $61.81M 10-Q · filed 2026-05-07 | $233.84M derived: sum of 2 quarters · filed 2026-05-07 | $379.56M derived: sum of 3 quarters · filed 2026-05-07 | $545.44M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $172.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $317.75M derived: sum of 2 quarters · filed 2026-03-30 | $483.63M derived: sum of 3 quarters · filed 2026-03-30 | $583.93M 10-K · filed 2026-03-30 |
| 2024-09-30 | $145.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $311.60M derived: sum of 2 quarters · filed 2025-11-10 | $411.90M 10-Q · filed 2025-11-10 | $436.38M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $165.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $266.18M 10-Q · filed 2025-08-14 | $290.66M derived: sum of 3 quarters · filed 2025-08-14 | $304.40M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $100.30M 10-Q · filed 2025-05-12 | $124.78M derived: sum of 2 quarters · filed 2025-05-12 | $138.51M derived: sum of 3 quarters · filed 2025-05-12 | $176.96M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $24.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $38.21M derived: sum of 2 quarters · filed 2025-03-03 | $76.65M derived: sum of 3 quarters · filed 2025-03-03 | $108.09M 10-K · filed 2025-03-03 |
| 2023-09-30 | $13.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $52.18M derived: sum of 2 quarters · filed 2024-11-14 | $83.61M 10-Q · filed 2024-11-14 | $150.44M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $38.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $69.88M 10-Q · filed 2024-08-12 | $136.71M derived: sum of 3 quarters · filed 2024-08-12 | $155.44M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $31.43M 10-Q · filed 2024-05-13 | $98.27M derived: sum of 2 quarters · filed 2024-05-13 | $117.00M derived: sum of 3 quarters · filed 2024-05-13 | $138.70M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $66.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $85.56M derived: sum of 2 quarters · filed 2024-03-26 | $107.26M derived: sum of 3 quarters · filed 2024-03-26 | $113.20M 10-K · filed 2024-03-26 |
| 2022-09-30 | $18.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $40.43M derived: sum of 2 quarters · filed 2023-11-13 | $46.36M 10-Q · filed 2023-11-13 | $80.84M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $21.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $27.63M 10-Q · filed 2023-08-07 | $62.11M derived: sum of 3 quarters · filed 2023-08-07 | $93.62M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $5.93M 10-Q · filed 2023-05-08 | $40.41M derived: sum of 2 quarters · filed 2023-05-08 | $71.92M derived: sum of 3 quarters · filed 2023-05-08 | $188.99M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $34.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $65.98M derived: sum of 2 quarters · filed 2023-03-06 | $183.05M derived: sum of 3 quarters · filed 2023-03-06 | $225.60M 10-K · filed 2023-03-06 |
| 2021-09-30 | $31.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $148.57M derived: sum of 2 quarters · filed 2022-11-03 | $191.12M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $117.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $159.62M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $42.55M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $82.70M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |